Suppr超能文献

单中心经验显示左西孟旦可用于接受心脏手术的儿童和心力衰竭失代偿的儿童。

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure.

机构信息

Department of Anesthesia and Intensive Care, Children's Hospital, Helsinki University, Central Hospital, P,O B, 281 Stenbäckinkatu 11, FIN-00029 HUCS Helsinki, Finland.

出版信息

BMC Anesthesiol. 2011 Oct 5;11:18. doi: 10.1186/1471-2253-11-18.

Abstract

BACKGROUND

Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room. We present the largest single-center experience of levosimendan in children.

METHODS

Retrospective analysis of all children who received levosimendan infusions between July 5, 2001 and July 4, 2010 in a pediatric intensive care unit. The results of a questionnaire for physicians (anesthesiologist/intensivists, cardiologists and cardiac surgeons) concerning their clinical perceptions of levosimendan are evaluated

RESULTS

During the study period a total of 484 infusions were delivered to 293 patients 53% of whom were male. The median age of the patients was 0.4 years (4 hours-21.1 years) at the time of levosimendan administration. A majority of levosimendan infusions were administered to children who were undergoing cardiac surgery (72%), 14% to children with cardiomyopathy and 14% to children with cardiac failure. Eighty-nine out of the 293 patients (30.4%) received repeated doses of levosimendan (up to 11 infusions). The most common indication for the use of levosimendan (94%) was when the other inotropic agents were insufficient to maintain stable hemodynamics. Levosimendan was especially used in children with cardiomyopathy (100%) or with low cardiac output syndrome (94%). A majority (89%) of the respondents believed that levosimendan administration postponed the need for mechanical assist devices in some children with cardiomyopathy. Moreover, 44% of respondents thought that the mechanical support was totally avoided in some patients undergoing cardiac surgery after receiving levosimendan.

CONCLUSION

Levosimendan is widely used in our institution and many physicians believe that its use could decrease the need for mechanical support in children undergoing cardiac surgery or in children with decompensated heart failure. However, there is a lack of good empirical evidence in children to support this perception.

摘要

背景

左西孟旦具有优于传统静脉正性肌力药物的药理学和血液动力学优势。它主要被用作儿科重症监护病房或手术室中的抢救药物。我们报告了左西孟旦在儿童中使用的最大单中心经验。

方法

回顾性分析 2001 年 7 月 5 日至 2010 年 7 月 4 日期间在儿科重症监护病房接受左西孟旦输注的所有儿童的资料。评估了医生(麻醉师/重症监护医师、心脏病专家和心脏外科医生)对左西孟旦临床认识的问卷调查结果。

结果

在研究期间,共向 293 名患者输注了 484 次左西孟旦,其中 53%为男性。接受左西孟旦治疗时,患者的中位年龄为 0.4 岁(4 小时-21.1 岁)。大多数左西孟旦输注是在接受心脏手术的儿童中进行的(72%),14%是在心肌病儿童中进行的,14%是在心力衰竭儿童中进行的。293 名患者中有 89 名(30.4%)接受了重复剂量的左西孟旦(多达 11 次输注)。使用左西孟旦的最常见指征(94%)是其他正性肌力药物不足以维持稳定的血液动力学。左西孟旦尤其用于心肌病儿童(100%)或低心输出综合征儿童(94%)。大多数(89%)受访者认为,在一些患有心肌病的儿童中,左西孟旦的给药可推迟对机械辅助设备的需求。此外,44%的受访者认为,在接受左西孟旦治疗后,一些接受心脏手术的患者完全避免了机械支持。

结论

左西孟旦在我们的机构中广泛使用,许多医生认为,它的使用可以减少心脏手术或心力衰竭失代偿的儿童对机械支持的需求。然而,儿童中缺乏支持这一观点的良好经验证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b602/3199236/96ce9266e2ce/1471-2253-11-18-1.jpg

相似文献

2
The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy.
World J Pediatr Congenit Heart Surg. 2017 Jan;8(1):25-31. doi: 10.1177/2150135116674466.
3
Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy.
Arch Cardiovasc Dis. 2015 Jun-Jul;108(6-7):347-55. doi: 10.1016/j.acvd.2015.01.012. Epub 2015 Apr 8.
5
Levosimendan for Hemodynamic Support after Cardiac Surgery.
N Engl J Med. 2017 May 25;376(21):2021-2031. doi: 10.1056/NEJMoa1616325. Epub 2017 Mar 21.
8
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
N Engl J Med. 2017 May 25;376(21):2032-2042. doi: 10.1056/NEJMoa1616218. Epub 2017 Mar 19.
9
Early experience with Levosimendan in children with ventricular dysfunction.
Pediatr Crit Care Med. 2006 Sep;7(5):445-8. doi: 10.1097/01.PCC.0000235251.14491.75.
10
Levosimendan: a review of its use in the management of acute decompensated heart failure.
Drugs. 2003;63(23):2651-71. doi: 10.2165/00003495-200363230-00009.

引用本文的文献

1
Recent and Upcoming Drug Therapies for Pediatric Heart Failure.
Front Pediatr. 2021 Nov 11;9:681224. doi: 10.3389/fped.2021.681224. eCollection 2021.
3
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.
Card Fail Rev. 2020 Jul 8;6:e19. doi: 10.15420/cfr.2020.03. eCollection 2020 Mar.
4
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
J Cardiovasc Pharmacol. 2020 Jul;76(1):4-22. doi: 10.1097/FJC.0000000000000859.
7
Use of Levosimendan in Postoperative Setting After Surgical Repair of Congenital Heart Disease in Children.
Pediatr Cardiol. 2018 Jan;39(1):19-25. doi: 10.1007/s00246-017-1718-2. Epub 2017 Sep 7.
9
Experience with levosimendan in 32 paediatric patients.
Pediatr Cardiol. 2015 Jun;36(5):1038-41. doi: 10.1007/s00246-015-1117-5. Epub 2015 Jan 22.

本文引用的文献

2
Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.
J Cardiothorac Vasc Anesth. 2011 Jun;25(3):419-24. doi: 10.1053/j.jvca.2010.07.004. Epub 2010 Sep 9.
3
Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials.
J Cardiothorac Vasc Anesth. 2010 Feb;24(1):51-7. doi: 10.1053/j.jvca.2009.05.031. Epub 2009 Aug 22.
4
Levosimendan in perioperative and critical care patients.
Curr Opin Anaesthesiol. 2009 Aug;22(4):496-501. doi: 10.1097/ACO.0b013e32832c5269.
5
[Levosimendan, a new inotropic drug: experience in children with acute heart failure].
Arch Argent Pediatr. 2009 Apr;107(2):139-45. doi: 10.1590/S0325-00752009000200008.
7
First experiences with intraoperative Levosimendan in pediatric cardiac surgery.
Eur J Pediatr. 2009 Jun;168(6):735-40. doi: 10.1007/s00431-008-0834-7. Epub 2008 Sep 24.
8
Clinical pharmacology of levosimendan.
Clin Pharmacokinet. 2007;46(7):535-52. doi: 10.2165/00003088-200746070-00001.
9
Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
Pediatr Crit Care Med. 2007 Jan;8(1):61-3. doi: 10.1097/01.PCC.0000253026.67341.5D.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验